Filing Details

Accession Number:
0000935836-25-000363
Form Type:
13G Filing
Publication Date:
2025-05-14 20:00:00
Filed By:
EcoR1 Capital
Company:
Kalaris Therapeutics Inc. (NASDAQ:KLRS)
Filing Date:
2025-05-15
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
EcoR1 Capital, LLC 0 201,718 1.1%
Oleg Nodelman 0 201,718 1.1%
EcoR1 Capital Fund Qualified, L.P. 0 191,242 1.0%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  Percentage calculated based on 18,702,413 shares of Common Stock outstanding on March 18, 2025, as reported in the Form 8-K filed by the Issuer on March 18, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  Percentage calculated based on 18,702,413 shares of Common Stock outstanding on March 18, 2025, as reported in the Form 8-K filed by the Issuer on March 18, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  Percentage calculated based on 18,702,413 shares of Common Stock outstanding on March 18, 2025, as reported in the Form 8-K filed by the Issuer on March 18, 2025.


SCHEDULE 13G


 
EcoR1 Capital, LLC
 
Signature:/s/ Oleg Nodelman
Name/Title:Manager
Date:05/15/2025
 
Oleg Nodelman
 
Signature:/s/ Oleg Nodelman
Name/Title:Reporting person
Date:05/15/2025
 
EcoR1 Capital Fund Qualified, L.P.
 
Signature:/s/ Oleg Nodelman
Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
Date:05/15/2025
Exhibit Information

EXHIBIT 99.1 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G